PerformanceRead the research
PT-141
10 mg
Bremelanotide, a cyclic melanocortin receptor agonist (functionally active at MC4R), studied in central sexual arousal and HSDD research (FDA approved as Vyleesi).
$50
For laboratory and research use only. Not for human or animal consumption.
Secure card checkout — instant order confirmation.
Specifications
| Format | Lyophilized powder |
|---|---|
| Amount per vial | 10 mg |
| Presentation | Single-use sealed vial |
| Storage | Store lyophilized vial refrigerated or frozen; once reconstituted, keep refrigerated (2–8°C). |
| Purity | Third-party tested to 99%+. |
| Intended use | Laboratory and research use only. |
Areas of Research Interest
- Central MC4R control of sexual motivation, bremelanotide is a canonical probe for studying brain-initiated versus vascular arousal pathways
- Female sexual desire neurobiology, the only approved on-demand melanocortin therapy, making it a reference tool for desire-distress research
- Male erectile and sexual-response signaling, legacy intranasal PT-141 datasets remain relevant to central-pathway research
- MC4R in energy balance and cardiovascular tone, appetite and satiety signaling, and the transient pressor response
- Melanocortin protection in circulatory shock, an established preclinical melanocortin-class theme mediated by MC4R
